Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function
The cytotoxic anti-cancer drugs cisplatin, paclitaxel, doxorubicin, 5-fluorouracil (5-FU), as
well as targeted drugs including imatinib, erlotinib, and nivolumab, play key roles in clinical …
well as targeted drugs including imatinib, erlotinib, and nivolumab, play key roles in clinical …
The role of marrow microenvironment in the growth and development of malignant plasma cells in multiple myeloma
N Giannakoulas, I Ntanasis-Stathopoulos… - International Journal of …, 2021 - mdpi.com
The development and effectiveness of novel therapies in multiple myeloma have been
established in large clinical trials. However, multiple myeloma remains an incurable …
established in large clinical trials. However, multiple myeloma remains an incurable …
del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma
J Corre, A Perrot, D Caillot, K Belhadj… - Blood, The Journal …, 2021 - ashpublications.org
Despite tremendous improvements in the outcome of patients with multiple myeloma in the
past decade, high-risk patients have not benefited from the approval of novel drugs. The …
past decade, high-risk patients have not benefited from the approval of novel drugs. The …
Targeting NF-κB signaling for multiple myeloma
Multiple myeloma (MM) is the second most common hematologic malignancy in the world.
Even though survival rates have significantly risen over the past years, MM remains …
Even though survival rates have significantly risen over the past years, MM remains …
Molecular and immunological mechanisms of clonal evolution in multiple myeloma
Multiple myeloma (MM) is a hematologic malignancy characterized by the proliferation of
clonal plasma cells in the bone marrow (BM). It is known that early genetic mutations in post …
clonal plasma cells in the bone marrow (BM). It is known that early genetic mutations in post …
Optical genome mapping reveals the complex genetic landscape of myeloma
A Giguère, I Raymond-Bouchard, V Collin, JS Claveau… - Cancers, 2023 - mdpi.com
Simple Summary Myeloma is a hematological cancer characterized by numerous genetic
abnormalities currently identified using fluorescent in situ hybridization (FISH). However …
abnormalities currently identified using fluorescent in situ hybridization (FISH). However …
High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions
P Hagen, J Zhang, K Barton - Blood cancer journal, 2022 - nature.com
Multiple myeloma (MM) is an acquired malignant plasma cell disorder that develops late in
life. Although progression free and overall survival has improved across all age, race, and …
life. Although progression free and overall survival has improved across all age, race, and …
[PDF][PDF] 血细胞相关比值与多发性骨髓瘤患者临床预后的相关性
余超， 吴玉玲， 张手丽， 李江， 汪勇， 曹慧 - 临床血液学杂志, 2023 - lcxyen.whuhzzs.com
目的: 分析外周血血细胞中的中性粒细胞/淋巴细胞比值(NLR), 单核细胞/淋巴细胞比值(MLR)
与多发性骨髓瘤(MM) 患者临床预后的关系. 方法: 纳入2015 年6 月至2020 年6 月收治的85 …
与多发性骨髓瘤(MM) 患者临床预后的关系. 方法: 纳入2015 年6 月至2020 年6 月收治的85 …
The Interplay between the DNA Damage Response (DDR) Network and the Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in Multiple Myeloma
The DNA damage response (DDR) network and the mitogen-activated protein kinase
(MAPK) signaling pathway are crucial mechanisms for the survival of all living beings. An …
(MAPK) signaling pathway are crucial mechanisms for the survival of all living beings. An …
A cancer-related microRNA signature shows biomarker utility in multiple myeloma
Multiple myeloma (MM) is the second most common hematological malignancy, arising from
terminally differentiated B cells, namely plasma cells. miRNAs are small non-coding RNAs …
terminally differentiated B cells, namely plasma cells. miRNAs are small non-coding RNAs …